GB0119243D0 - Antitumoral analogs of ET-743 - Google Patents

Antitumoral analogs of ET-743

Info

Publication number
GB0119243D0
GB0119243D0 GBGB0119243.4A GB0119243A GB0119243D0 GB 0119243 D0 GB0119243 D0 GB 0119243D0 GB 0119243 A GB0119243 A GB 0119243A GB 0119243 D0 GB0119243 D0 GB 0119243D0
Authority
GB
United Kingdom
Prior art keywords
antitumoral
analogs
antitumoral analogs
ecteinascidin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0119243.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9919954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0119243(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority to GBGB0119243.4A priority Critical patent/GB0119243D0/en
Publication of GB0119243D0 publication Critical patent/GB0119243D0/en
Priority to RU2004106617/04A priority patent/RU2283842C2/ru
Priority to EP10180740A priority patent/EP2270018A1/en
Priority to SI200230647T priority patent/SI1414828T1/sl
Priority to MXPA04001240A priority patent/MXPA04001240A/es
Priority to CA2455768A priority patent/CA2455768C/en
Priority to PL367940A priority patent/PL218295B1/pl
Priority to KR10-2004-7001924A priority patent/KR20040032150A/ko
Priority to AT02753134T priority patent/ATE374777T1/de
Priority to PT02753134T priority patent/PT1414828E/pt
Priority to JP2003519076A priority patent/JP4684552B2/ja
Priority to CNB028196511A priority patent/CN100334094C/zh
Priority to PCT/GB2002/003592 priority patent/WO2003014127A1/en
Priority to HU0401174A priority patent/HU229779B1/hu
Priority to DK02753134T priority patent/DK1414828T3/da
Priority to DE60222775T priority patent/DE60222775T2/de
Priority to IL16005102A priority patent/IL160051A0/xx
Priority to AU2002313540A priority patent/AU2002313540B2/en
Priority to EP07001308A priority patent/EP1806349A1/en
Priority to ES02753134T priority patent/ES2294151T3/es
Priority to HK04108496.8A priority patent/HK1065786B/en
Priority to EP02753134A priority patent/EP1414828B9/en
Priority to US10/485,536 priority patent/US7763615B2/en
Priority to NZ530837A priority patent/NZ530837A/en
Priority to IL160051A priority patent/IL160051A/en
Priority to NO20040961A priority patent/NO337476B1/no
Priority to CY20071101576T priority patent/CY1107830T1/el
Priority to JP2010209928A priority patent/JP2011026331A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0119243.4A 2001-08-07 2001-08-07 Antitumoral analogs of ET-743 Ceased GB0119243D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743
US10/485,536 US7763615B2 (en) 2001-08-07 2002-08-06 Ecteinascidin analogs for use as antitumour agents
NZ530837A NZ530837A (en) 2001-08-07 2002-08-06 Derivatives of ecteinascidin 736 as antitumoral analogs
HU0401174A HU229779B1 (en) 2001-08-07 2002-08-06 Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
DK02753134T DK1414828T3 (da) 2001-08-07 2002-08-06 Antitumoranaloger
SI200230647T SI1414828T1 (sl) 2001-08-07 2002-08-06 Protitumorski analogi
MXPA04001240A MXPA04001240A (es) 2001-08-07 2002-08-06 Analogos antitumorales.
CA2455768A CA2455768C (en) 2001-08-07 2002-08-06 Antitumoral analogs of et-736
PL367940A PL218295B1 (pl) 2001-08-07 2002-08-06 Pochodne ekteinascydyny, kompozycja je zawierająca oraz ich zastosowanie
KR10-2004-7001924A KR20040032150A (ko) 2001-08-07 2002-08-06 항종양 동족체
AT02753134T ATE374777T1 (de) 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen
PT02753134T PT1414828E (pt) 2001-08-07 2002-08-06 Análogos anti-tumorais
JP2003519076A JP4684552B2 (ja) 2001-08-07 2002-08-06 抗腫瘍類似体
CNB028196511A CN100334094C (zh) 2001-08-07 2002-08-06 抗肿瘤类似物
PCT/GB2002/003592 WO2003014127A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs
RU2004106617/04A RU2283842C2 (ru) 2001-08-07 2002-08-06 Производные эктеинасцидина, их применение и фармацевтическая композиция
EP10180740A EP2270018A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs
DE60222775T DE60222775T2 (de) 2001-08-07 2002-08-06 Analoga als antitumorale verbindungen
IL16005102A IL160051A0 (en) 2001-08-07 2002-08-06 Ecteinascidin derivatives and pharmaceutical compositions containing the same
AU2002313540A AU2002313540B2 (en) 2001-08-07 2002-08-06 Antitumoral analogs
EP07001308A EP1806349A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs
ES02753134T ES2294151T3 (es) 2001-08-07 2002-08-06 Analogos antitumorales.
HK04108496.8A HK1065786B (en) 2001-08-07 2002-08-06 Antitumoral analogs
EP02753134A EP1414828B9 (en) 2001-08-07 2002-08-06 Antitumoral analogs
IL160051A IL160051A (en) 2001-08-07 2004-01-26 Ecteinascidin derivatives and pharmaceutical compositions containing the same as anti-cancer medicaments
NO20040961A NO337476B1 (no) 2001-08-07 2004-03-05 Derivater av ecteinascidinene, farmasøytiske preparater derav, og deres anvendelse ved fremstillingen av et medikament for behandling av kreft.
CY20071101576T CY1107830T1 (el) 2001-08-07 2007-12-12 Αντικαρκινικα αναλογα
JP2010209928A JP2011026331A (ja) 2001-08-07 2010-09-17 抗腫瘍類似体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743

Publications (1)

Publication Number Publication Date
GB0119243D0 true GB0119243D0 (en) 2001-10-03

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0119243.4A Ceased GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743

Country Status (22)

Country Link
US (1) US7763615B2 (https=)
EP (3) EP1414828B9 (https=)
JP (2) JP4684552B2 (https=)
KR (1) KR20040032150A (https=)
CN (1) CN100334094C (https=)
AT (1) ATE374777T1 (https=)
AU (1) AU2002313540B2 (https=)
CA (1) CA2455768C (https=)
CY (1) CY1107830T1 (https=)
DE (1) DE60222775T2 (https=)
DK (1) DK1414828T3 (https=)
ES (1) ES2294151T3 (https=)
GB (1) GB0119243D0 (https=)
HU (1) HU229779B1 (https=)
IL (2) IL160051A0 (https=)
MX (1) MXPA04001240A (https=)
NO (1) NO337476B1 (https=)
NZ (1) NZ530837A (https=)
PL (1) PL218295B1 (https=)
PT (1) PT1414828E (https=)
RU (1) RU2283842C2 (https=)
WO (1) WO2003014127A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
RU2562432C2 (ru) 2010-11-26 2015-09-10 Нек Корпорейшн Устройство видеокодирования, устройство видеодекодирования, способ видеокодирования, способ видеодекодирования и программа
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
TW202116783A (zh) 2019-09-03 2021-05-01 西班牙商瑪製藥股份有限公司 盧比克替定治療惡性間皮瘤
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
KR20230004714A (ko) 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2022048775A1 (en) 2020-09-04 2022-03-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
IN202141039393A (https=) * 2021-08-31 2023-03-03
US20240415834A1 (en) 2021-11-08 2024-12-19 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en) 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
IL160051A (en) 2012-01-31
JP2011026331A (ja) 2011-02-10
CN100334094C (zh) 2007-08-29
HUP0401174A3 (en) 2005-12-28
CN1564822A (zh) 2005-01-12
EP2270018A1 (en) 2011-01-05
EP1414828B9 (en) 2008-02-20
PL367940A1 (en) 2005-03-07
US7763615B2 (en) 2010-07-27
JP4684552B2 (ja) 2011-05-18
DK1414828T3 (da) 2008-02-04
AU2002313540B2 (en) 2008-05-22
CA2455768C (en) 2011-10-11
WO2003014127A1 (en) 2003-02-20
RU2283842C2 (ru) 2006-09-20
ATE374777T1 (de) 2007-10-15
DE60222775T2 (de) 2008-07-17
NO20040961L (no) 2004-03-05
NZ530837A (en) 2005-07-29
HUP0401174A2 (hu) 2005-09-28
DE60222775D1 (de) 2007-11-15
EP1806349A1 (en) 2007-07-11
CA2455768A1 (en) 2003-02-20
US20060128711A1 (en) 2006-06-15
CY1107830T1 (el) 2013-06-19
PT1414828E (pt) 2007-12-27
KR20040032150A (ko) 2004-04-14
HK1065786A1 (en) 2005-03-04
ES2294151T3 (es) 2008-04-01
RU2004106617A (ru) 2005-04-10
PL218295B1 (pl) 2014-11-28
MXPA04001240A (es) 2004-06-03
IL160051A0 (en) 2004-06-20
EP1414828B1 (en) 2007-10-03
NO337476B1 (no) 2016-04-18
HU229779B1 (en) 2014-07-28
JP2005501093A (ja) 2005-01-13
EP1414828A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
GB0119243D0 (en) Antitumoral analogs of ET-743
TW263423B (https=)
MXPA04000877A (es) Derivados retinoides con actividades antiangiogenicas, antitumorales y proapoptoticas.
SI1280809T1 (sl) Antitumorski ekteinascidin derivati
HUP0400648A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
DE60112974D1 (en) Carbolinderivate
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
MY120090A (en) Chemical compounds.
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
EP1385514A4 (en) SPIROINDEN AND SPIROINDAN COMPOUNDS
IL160437A0 (en) INDENO [1,2-c] ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
GB9923077D0 (en) Sapogenin derivatives and their use
PL338508A1 (en) Nucleophylically substituted enteinascines and their n-oxides
DE60216233D1 (en) Carbolinderivate
IT1307267B1 (it) Procedimento di rafforzamento di attivita' antitumorale di farmacigrezzi, composizione contenente un farmaco grezzo rafforzante
MXPA04000506A (es) Nuevos derivados de et-743 antitumorales.
IL158879A0 (en) PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-(2,3-f) QUINOLINE
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
GB0218816D0 (en) Antitumoral analogs of lamellarins
PL1664093T3 (pl) Przeciwnowotworowe związki na bazie kahalalidu F
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
GB9921578D0 (en) Omeprazole synthesis
SI1406907T1 (sl) Anti tumorski derivati et-743
GB0022644D0 (en) Antitumoral derivatives of ET-743

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)